Xueya Zhao

Dr. Xueya Zhao

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
ZLZhigang Li
Zhigang Li
JFJiankun Fan
Jiankun Fan
YXYalan Xiao
Yalan Xiao
WWWei Wang
Wei Wang
CZChanglin Zhen
Changlin Zhen
YHYu Hou
Yu Hou

1 January 2024 in Aging and disease
Verified
Journal Article
Open access
PDF file
WXWenhua Xie
Wenhua Xie
YCYewei Cui
Yewei Cui
LYLingzhi Yue
Lingzhi Yue
TZTing Zhang
Ting Zhang
CHChenglong Huang
Chenglong Huang
XLXi Li
Xi Li
Reduced adipogenesis is a prominent characteristic of aging adipose tissue and is closely tied to the development of metabolic disorders associated with aging. Epigenetic modification plays a crucial role in the aging process, yet the role of N6-methyladenosine (m6A), the most prevalent RNA modification, in regulating adipose tissue aging remains uncertain. Our study found that levels of m6A and its recognition protein, heterogeneous nuclear ribonucleoprotein C (HNRNPC), decrease in adipose tissue as individuals age. Lower levels of HNRNPC were also linked to reduced adipogenesis during aging. Through loss and gain of function experiments with HNRNPC, we established a positive correlation between HNRNPC and adipogenesis in vitro. Hnrnpc-APKO mice displayed decreased adipogenesis, increased insulin resistance, elevated expression of aging-related and inflammation-related genes, decreased lipogenesis-related genes, and other metabolic disorders compared to their littermates. Additionally, we discovered that HNRNPC facilitated the stability of lymphocyte cytosolic protein 1 (Lcp1) mRNA by binding to the m6A motif of LCP1. Overexpression of LCP1 mitigated the inhibition of adipogenesis caused by decreased HNRNPC through modulation of cytoskeletal remodeling. Finally, our findings demonstrate that anti-aging treatments could enhance HNRNPC levels. In conclusion, HNRNPC is positively associated with reduced adipogenesis during aging, and increacing HNRNPC levels through anti-aging treatments highlights its potential as a therapeutic target for addressing metabolic imbalances in adipose tissue related to aging.

22 July 2025 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YLYanhong Luo
Yanhong Luo
JLJie Luo
Jie Luo
MYMin Yang
Min Yang
XZXueya Zhao
Xueya Zhao
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is often resistant to conventional therapies. The present narrative review discusses on the role of T cell metabolic reprogramming in the AML tumor microenvironment (TME), which markedly impacts the effectiveness of immunotherapy. The TME of AML, influenced by factors such as high lactic acid (LA) levels, hypoxia and nutrient competition, hampers T cell functions such as glycolysis, lipid metabolism and amino acid metabolism, leading to impaired T cell proliferation and antitumor response. Metabolic waste products, including LA and adenosine, further contribute to the immunosuppressive environment. T cell exhaustion, induced by nutrient deprivation and metabolic dysregulation, serves a key role in the failure of immune responses. Moreover, strategies to modulate T cell metabolism, such as targeting glycolysis and fatty acid oxidation, show promise in enhancing immunotherapy outcomes. The current review also highlights emerging technologies, such as single‑cell metabolomics and CRISPR screening, which are critical for identifying metabolic targets and advancing personalized therapies. Despite challenges in translating these findings to clinical settings, understanding T cell metabolism in the AML TME offers new therapeutic avenues for improving patient outcomes.

21 January 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
ZCZhe Chen
Zhe Chen
FWFeng Wu
Feng Wu
YLYan Li
Yan Li
LLLei Li
Lei Li
YLYufei Lei
Yufei Lei
YHYu Hou
Yu Hou
Hematopoietic stem cells (HSCs) are susceptible to replication stress, which is a major contributor to HSC defects in Fanconi anemia (FA). Here, we report that HSCs relax the global chromatin by downregulating the expression of a chromatin architectural protein, DEK, in response to replication stress. DEK is abnormally accumulated in bone marrow (BM) CD34+ cells from patients with FA and in Fancd2-deficient HSCs. DEK haploinsufficiency promotes chromatin relaxation, replication stress relief, and function recovery of Fancd2-deficient HSCs. Furthermore, inhibition of DEK restores the proliferation of FA CD34+ cells in vitro and enhances their engraftment in vivo. Mechanistically, the activating transcription factor 2 (ATF2), specifically phosphorylated ATF2 at Thr69/71, was identified as a promoter of DEK transcription. Fancd2 deficiency results in p38 hyperphosphorylation, which in turn phosphorylates ATF2 at Thr69/71, leading to DEK accumulation in HSCs. In conclusion, our findings establish a functional link between chromatin relaxation and replication stress tolerance in HSCs and highlight DEK as a target for FA.

13 December 2025 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
LYLingbo Yi
Lingbo Yi
FZFuyun Zhu
Fuyun Zhu
LLLun Liu
Lun Liu
RZRunlong Zhao
Runlong Zhao
YLYanhong Luo
Yanhong Luo
XZXueya Zhao
Xueya Zhao
The Monopterus albus serves as a unique model for studying sex reversal, transitioning naturally from female to male. However, the origins of male germline

25 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJianming Wang
Jianming Wang
QGQiang Gong
Qiang Gong
YFYinghao Fu
Yinghao Fu
YLYijia Liu
Yijia Liu
YLYu Luo
Yu Luo
XZXueya Zhao
Xueya Zhao
Leukemia stem cells (LSCs) primarily rely on mitochondrial oxidative phosphorylation (OXPHOS) for energy production, a metabolic feature that inevitably generates excessive reactive oxygen species (ROS). NYNRIN (NYN domain and retroviral integrase containing) is highly expressed in LSC-like cells and is associated with poor prognosis in patients with acute myeloid leukemia (AML). Genetic targeting of NYNRIN impairs LSC-like cell maintenance and in vivo leukemogenic capacity in MLL-AF9- and HOXA9/MEIS1-driven AML models, and compromises the in vivo pathogenicity of patient-derived LSC-like cells. Mechanistically, NYNRIN sustains thioredoxin (Trx) activity by functioning as an RNA-binding protein that directly binds and degrades TXNIP mRNA via its NYN domain. Loss of NYNRIN stabilizes TXNIP mRNA, leading to TXNIP accumulation, which disrupts Trx-mediated redox buffering, induces ROS overproduction and mitochondrial dysfunction, and triggers LSC apoptosis. Notably, NYNRIN inhibition potentiates venetoclax efficacy by compromising Trx-mediated ROS clearance, lowering the apoptotic threshold of LSCs. Collectively, our findings reveal a critical NYNRIN-TXNIP-Trx axis that safeguards LSCs by enabling efficient ROS clearance.